TikoMed’s ILB® activates the body’s natural repair signals to restore glutamate homeostasis, amino acid metabolism and neurocognitive functions in a rat model of severe traumatic brain injury

VIKEN, Sweden, Aug. 3, 2022 /PRNewswire/ — A new study with TikoMed’s lead drug candidate, ILB®, addressing underlying causes of neurodegeneration in acute and chronic diseases, was published in the International Journal of Molecular Sciences today. The data from the rodent model…